Skip to main content
HISAMITSU PHARMACEUTICAL CO.,INC. logo

HISAMITSU PHARMACEUTICAL CO.,INC. — Investor Relations & Filings

Ticker · 4530 ISIN · JP3784600003 LEI · 5299006QL3IBQ4CN7E12 T Manufacturing
Open in API
Filings indexed 69 across all filing types
Latest filing 2025-05-23 AGM Information
Country JP Japan
Listing T 4530

About HISAMITSU PHARMACEUTICAL CO.,INC.

https://global.hisamitsu/

Hisamitsu Pharmaceutical Co., Inc. is a pharmaceutical company that develops, manufactures, and markets a range of prescription and over-the-counter (OTC) products. The company specializes in external pain relief medications, utilizing advanced transdermal drug delivery system (TDDS) technology. Its core product portfolio includes topical analgesics and anti-inflammatory formulations, such as plasters, patches, and poultices. A key brand in its OTC segment is Salonpas, a globally recognized line of pain-relieving patches. The company serves both consumer healthcare and prescription markets worldwide, focusing on providing solutions for musculoskeletal pain and inflammation.

Recent filings

Filing Released Lang Actions
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 ('提出理由') that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act, following resolutions passed at the Annual General Meeting (AGM) held on May 22, 2025. Section 2 ('報告内容') details the resolutions, including dividend approval (剰余金処分の件) and the election of directors (取締役10名選任の件), along with the voting results. This structure—a formal report detailing the outcomes of a shareholder meeting—is characteristic of an AGM Results filing. In the provided definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit for reporting the official results of shareholder votes from a general meeting.
2025-05-23 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO of Hisamitsu Pharmaceutical Co., Inc. regarding the accuracy of the interim report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like an interim report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 123
2024-10-11 Japanese
半期報告書－第123期(2024/03/01－2025/02/28)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Hisamitsu Pharmaceutical Co., Inc. with the Kanto Local Finance Bureau. It contains comprehensive financial data, including consolidated financial statements, management analysis (MDA), and details on shareholdings for the interim period (March 1, 2024, to August 31, 2024). As it is a formal, comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. H1 2025
2024-10-11 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, Article 24-4-8, Paragraph 1. It serves as an officer certification by the CEO of Hisamitsu Pharmaceutical Co., Inc. regarding the accuracy of the quarterly report. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report, should be classified as Regulatory Filings (RNS). Q1 123
2024-07-12 Japanese
四半期報告書－第123期第1四半期(2024/03/01－2024/05/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '四半期報告書' (Quarterly Report) filed by Hisamitsu Pharmaceutical Co., Inc. with the Kanto Local Finance Bureau. It contains detailed financial statements, including the balance sheet and income statement for the first quarter of the 123rd fiscal period (March 1, 2024, to May 31, 2024). As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report (IR). Q1 2025
2024-07-12 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (909 characters) and contains a table structure typical of Japanese regulatory filings, specifically mentioning "【提出書類】確認書" (Filing Document: Confirmation Document) and referencing the Financial Instruments and Exchange Act ("金融商品取引法"). The core content confirms that the Representative Director and President has verified the appropriateness of the contents of the company's Annual Securities Report ("有価証券報告書") for the 122nd fiscal period (ending Feb 29, 2024). This document is a formal confirmation statement regarding the accuracy of a primary filing (the Annual Securities Report, which corresponds to a 10-K in US terms). Since this is a confirmation document related to the annual filing, and not the full 10-K itself, and it is a specific regulatory confirmation, it fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for a 'Confirmation of Annual Report Accuracy'. Given its regulatory nature and brevity, RNS is the most appropriate fallback. FY 2024
2024-05-24 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.